StockData
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31

Tilray Brands, Inc.

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$3.03−0.01 (-0.33%)

Close on Oct 19, 2026

Market cap
$404.02M
P/E (TTM)
–
Dividend yield
–

Tilray Brands, Inc. revenue by segment

By business segment

RevenueQ4 26Q3 26Q2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24% of revenueYoY
Beverage Alcohol Business [Member]$105.60M$42.56M$50.08M$55.74M$65.62M$55.92M$63.08M$55.97M$76.74M$54.69M$46.51M$24.16M37.5%+60.9%
Distribution Business [Member]$84.96M$82.96M$85.32M$74.01M$74.05M$61.49M$67.61M$68.07M$65.57M$56.79M$67.22M$69.16M30.2%+14.7%
Cannabis Segment [Member]$71.47M$64.83M$67.53M$64.51M$67.83M$54.27M$65.65M$61.25M$71.92M$63.43M$67.11M$70.33M25.4%+5.4%
Wellness Business [Member]$19.69M$16.38M$14.58M$15.24M$17.04M$14.09M$14.61M$14.75M$15.66M$13.43M$12.93M$13.30M7.0%+15.6%
Tilray Pharma Segment [Member]–––––––$68.07M$65.57M$56.79M–$69.16M––

By product or service

By region

RevenueQ4 26Q3 26Q2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24% of revenueYoY
EMEA [Member]$152.34M$104.96M$103.16M$85.25M$94.04M$72.39M$79.25M$77.67M$74.31M$67.14M$75.29M$79.70M54.1%+62.0%
United States$68.91M$51.68M$57.84M$63.96M$73.64M$64.42M$71.75M$63.88M$85.89M$62.38M$53.37M$31.49M24.5%-6.4%
Canada$55.10M$48.22M$54.17M$58.17M$54.31M$45.93M$56.72M$55.91M$65.31M$55.14M$61.25M$62.03M19.6%+1.5%
Rest of World [Member]$5.37M$1.87M$2.34M$2.12M$2.55M$3.04M$3.22M$2.59M$4.37M$3.67M$3.86M$3.72M1.9%+110.6%
North America [Member]–––––––––$117.52M$114.62M$93.52M––

From the segment and revenue-disaggregation notes of Tilray Brands's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.